Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
Ali R, Virendra SA, Chawla PA
Selain itu, antioksidan dalam dua bahan aktif ini akan membantu melindungi kulit dari paparan sinar UV dan radikal bebas
Heres what the science says.
Many of these prescription claims were written by doctors living many states away from their patients
Frequently Asked Questions What is Cyto-Matrix, and how are its supplements different from retail brands